Our strategic focus on medical dermatology
boosted by
our sustained investment in R&D
+
strategic partnerships
Growing the business and innovating
In 2025, Almirall delivered outstanding financial results while continuing to advance its R&D pipeline, reflecting the strength of our strategic focus on medical dermatology.
Our financial success supported by
2025 was a strong year for Almirall, meeting guidance and achieving solid growth driven by its focus on medical dermatology and strong execution. Double-digit increases in net sales and EBITDA reflected operational strength, while a net debt/EBITDA ratio of 0x supported continued investment in R&D and portfolio expansion for long-term growth.
Net sales€1,108.1 MM
R&D investment€138.1 MM
(12.5% of net sales)
EBITDA€232.9 MM
Cash flow from operating activities€174.5 MM
Normalized net income€52.6 MM
Net debtnet debt/
EBITDA
ratio 0x
Our dermatology portfolio
Check it out
Breakdown of Net Sales by geography
1/3
€ MillionFY 2025FY 2024% CHG YoY
Europe1,005.9875.214.9%
Dermatology608.0484.125.6%
General Medicine & OTC397.9391.61.7%
Net sales Europe
2025
2024
+14.9% YoY
growth1,005.9€ MM89% EU45% - 55%
45.2€ MM5.8% US2% - 98%
57.0€ MM5.2% RoW15% - 85%
Dermatology
General medicine & OTC